Incyte Skin Drug Trial Succeeds as Stock Nears $90

Edgen Stock·Mar 28 2026, 19:20

Share to

Share to

Copy link

Key Takeaways

Incyte announced positive late-stage trial results for an experimental skin disease drug on March 28, providing a crucial pipeline update for the biopharmaceutical firm. The news arrives as the company's stock navigates a period of volatility and heightened competition.

Positive Trial Results: Incyte reported on March 28 that its experimental drug demonstrated long-term symptom relief in two late-stage trials, a key step toward potential regulatory approval.
Conflicting Market Signals: Despite the positive news, Incyte's stock (INCY) closed its last session at $90.62, down 10.56% over the past 30 days, and analysts are divided, with price targets ranging from $75 (Sell) to a consensus of $110.53 (Moderate Buy).
Intensifying Competition: On the same day, competitor Alumis Inc. released strong Phase 3 data for its own oral psoriasis drug, envudeucitinib, signaling a highly competitive market for new dermatology treatments.

Incyte Reports Positive Late-Stage Trial Data

Biopharmaceutical firm Incyte announced on March 28, 2026, that its experimental drug for a skin condition successfully demonstrated long-term symptom reduction in two separate late-stage trials. This positive outcome is a significant milestone, potentially paving the way for a new revenue stream if the drug secures regulatory approval. For Incyte, which relies heavily on its flagship drug Jakafi, diversifying its late-stage pipeline is a core strategic priority to drive future growth.

Stock Faces Headwinds Despite 46% One-Year Gain

The trial success contrasts with Incyte's recent stock performance. While boasting a strong 45.97% total shareholder return over the past year, the stock has recently weakened, with its price at $90.62 reflecting a 10.56% decline over the last 30 days. Analyst sentiment is sharply divided, illustrating the market's uncertainty. BMO Capital maintains a "Sell" rating with a $75.00 price target, citing valuation concerns. This stands in opposition to a consensus "Moderate Buy" rating and an average price target of $110.53, which suggests some on Wall Street believe the recent dip presents a buying opportunity.

Competitor Alumis Intensifies Psoriasis Market Race

Incyte's pipeline advancement does not occur in a vacuum. On the same day, competitor Alumis Inc. unveiled robust data from its own Phase 3 trials for envudeucitinib, an oral drug targeting moderate-to-severe plaque psoriasis. Alumis reported that a significant percentage of patients achieved near-complete skin clearance (PASI 90), highlighting the intense competition Incyte will face. The parallel announcements underscore the high-stakes race to capture market share in the lucrative immunology and dermatology sectors, where novel oral treatments are in high demand.